NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
OPRA Shareholders Click Here: https://www.zlk.com/pslra-1/opera-limited-loss-form?prid=5628&wire=1
GERN Shareholders Click Here: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5628&wire=1
CAN Shareholders Click Here: https://www.zlk.com/pslra-1/canaan-inc-loss-form?prid=5628&wire=1
* ADDITIONAL INFORMATION BELOW *
Opera Limited (OPRA)
OPRA Lawsuit on behalf of: investors who purchased (a) Opera American depositary shares pursuant and/or traceable to the Company's initial public offering commenced on or about July 27, 2018 and/or (b) Opera securities between July 27, 2018 and January 15, 2020,
Lead Plaintiff Deadline: March 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/opera-limited-loss-form?prid=5628&wire=1
According to the filed complaint, (i) Opera's sustainable growth and market opportunity for its browser applications was significantly overstated; (ii) Defendants' funded, owned, or otherwise controlled loan services applications and/or businesses relied on predatory lending practices; (iii) all the foregoing, once revealed, were reasonably likely to have a material negative impact on Opera's financial prospects, especially with respect to its lending applications' continued availability on the Google Play Store; and (iv) as a result, the Offering Documents and Defendants' statements were materially false and/or misleading and failed to state information required to be stated therein.
Geron Corporation (GERN)
GERN Lawsuit on behalf of: investors who purchased March 19, 2018 - September 26, 2018
Lead Plaintiff Deadline: March 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5628&wire=1
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
Canaan Inc. (CAN)
CAN Lawsuit on behalf of: investors who purchased publicly traded securities of Canaan, including its American Depository Shares pursuant and/or traceable to the Company's registration statement and related prospectus issued in connection with the Company's November 20, 2019 initial public offering.
Lead Plaintiff Deadline: May 4, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/canaan-inc-loss-form?prid=5628&wire=1
According to the filed complaint, (1) the purported "strategic cooperation" was actually a transaction with a related party; (2) the company's financial health was worse than what was actually reported; (3) the company had recently removed numerous distributors from its website just prior to the initial public offering, many of which were small or suspicious businesses; and (4) several of the Company's largest Chinese clients in prior years were clients who were not in the Bitcoin mining industry and, thus, would likely not be repeat customers.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: